American Vanguard Corporation (AVD) Market Cap
American Vanguard Corporation has a market capitalization of $78.8M.
Financials based on reported quarter end 2025-12-31
Price: $2.76
▼ -0.21 (-7.07%)
Market Cap: 78.77M
NYSE · time unavailable
CEO: Douglas A. Kaye
Sector: Basic Materials
Industry: Agricultural Inputs
IPO Date: 1987-03-03
Website: https://www.american-vanguard.com
American Vanguard Corporation (AVD) - Company Information
Market Cap: 78.77M · Sector: Basic Materials
American Vanguard Corporation, through its subsidiaries, develops, manufactures, and markets specialty chemicals for agricultural, commercial, and consumer uses in the United States and internationally. It manufactures and formulates chemicals, including insecticides, fungicides, herbicides, molluscicides, soil health, plant nutrition, growth regulators, and soil fumigants in liquid, powder, and granular forms for crops, turf and ornamental plants, and human and animal health protection. The company also markets, sells, and distributes end-use chemical and biological products for crop applications; and distributes chemicals for turf and ornamental markets. It distributes its products through national distribution companies, and buying groups or co-operatives; and through sales offices, sales force executives, sales agents, and wholly owned distributors. The company was incorporated in 1969 and is headquartered in Newport Beach, California.
Analyst Sentiment
Based on 13 ratings
Analyst 1Y Forecast: $0.00
Average target (based on 2 sources)
Consensus Price Target
Low
$14
Median
$17
High
$20
Average
$17
Potential Upside: 515.9%
Price & Moving Averages
Related Companies in Basic Materials
ASCENT INDUSTRIES (ACNT)
Basic Materials
$0.14B
Mkt Cap
FRIEDMAN INDUSTRIES INC (FRD)
Basic Materials
$0.14B
Mkt Cap
TRINSEO PLC (TSE)
Basic Materials
$0.00B
Mkt Cap
SMITH MIDLAND CORP (SMID)
Basic Materials
$0.18B
Mkt Cap
FUTUREFUEL CORP (FF)
Basic Materials
$0.19B
Mkt Cap
CLEARWATER PAPER CORP (CLW)
Basic Materials
$0.24B
Mkt Cap
Fundamentals Overview
📊 AI Financial Analysis
Powered by StockMarketInfo"AVD reported revenue of $150.7M for the year ending December 31, 2025, but posted a net loss of $28.2M. The company generated an operating cash flow of $31.1M and maintained a healthy free cash flow of $26.2M despite negative net income. Total assets stood at $596.5M against total liabilities of $404.1M, leading to total equity of $192.4M. The substantial net debt of $179M raises concerns about leverage. AVD has a history of paying dividends, with recent payments at $0.03 per share, yet the overall shareholder returns are negatively impacted due to a drastic 46.56% decline in stock price over the past year. The current share price of $2.33 is significantly lower than the target consensus of $17, indicating possible undervaluation if sentiment shifts positively. However, given the negative earnings and recent stock performance, caution is warranted in assessing potential recovery."
Revenue Growth
Revenue of $150.7M shows potential for growth but lacks the context of previous years.
Profitability
Negative net income indicates ongoing financial struggles.
Cash Flow Quality
Strong free cash flow of $26.2M showcases the company's ability to generate cash.
Leverage & Balance Sheet
High net debt relative to equity raises concerns about financial stability.
Shareholder Returns
Shareholder returns adversely affected by significant stock price decline.
Analyst Sentiment & Valuation
Current price significantly below target consensus suggests potential undervaluation.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.
Management is clearly pointing to operational execution: adjusted EBITDA surged to $8.2M (+350%+ YoY) and gross margin expanded by 300 bps YoY, supported by manufacturing efficiency (LA→Alabama), better SIOP/inventory dynamics, and reduced incentives (herbicides notably Impact/Envoke/Aztec). They also maintained full-year adjusted EBITDA guidance ($40M–$44M) while lowering 2025 net sales to $520M–$535M due to regional softness (Mexico, Central America, Australia). The Q&A reveals the key hard overhang: the Specialty product-liability matter. Even though management believes claims will be reimbursed, they had to record the expected expense without recording offsetting indemnification assets (yet), creating near-term earnings risk. Another pressure point—tariff uncertainty—was framed as analyzed and mitigated (lower COGS/raw material trends offset tariff impact). Analysts probed free cash flow and leverage; management effectively endorsed an ~ $20M annual FCF pencil and reiterated the goal to get leverage <3 via debt paydown.
Growth Catalysts
- Q4/Q1 expected rebound in Specialty growth after product liability claims processing improved (management: not expected to be long-term impact)
- U.S. crop normalization with easing incentives in channel; herbicide momentum (Impact, Envoke, Aztec) into Q4
- Geographic expansion and expansion into new crops/sectors contributing to a stated ~$100 million medium-term net sales growth portfolio
- Factory utilization improvement from incremental growth/volume supporting lower cost structure
Business Development
- Specialty mosquito control/advanced technologies (mosquito adulticide, home pest control, ornamental/greenhouse, golf course, lawn & landscape)
- Folex product cited as benefitting from being a U.S. domestic supplier/producer with increased volumes expected in 2026
- Senior lenders agreement reached to extend credit facility term to December 31, 2026
Financial Highlights
- Adjusted EBITDA: $8.2M in Q3 2025 vs $1.8M in Q3 2024 (+350%+); company stated Q3 is seasonally weakest and Q4 strongest
- Adjusted gross profit margin improved by +300 bps year-over-year (CFO later quantified GAAP gross margin at 29% vs 15% in the prior year period); CFO noted Q3 2024 had a nonrecurring item and adjusted gross margin would have been 26% in Q3 2024
- U.S. GAAP revenue: $119M in Q3 2025 vs $118M in Q3 2024 (+1%); CFO noted adjusted prior-year revenue would have been ~$130M due to a nonrecurring item
- Operating expense reduction: down ~$6M vs Q3 2024 and down $14M for 9-month period; CFO also cited operating costs down 11% or ~$5M in Q3 and $18M or 14% year-to-date
- Specialty impacted in early Q3 by product liability matter; Q3 recorded expense related to expected settlement costs (management: fully reimbursed in future, but indemnification assets not recorded due to insufficient information)
- Net trade working capital: ~$24M lower vs same period last year; inventory: ~$47M lower
- Net debt: decreased ~$2M to ~$165M vs prior year period; management reduced early pay materially in Q3 2025 vs Q3 2024
Capital Funding
- CapEx guidance: $5M–$6M for 2025
- Free cash flow use: virtually all free cash flow expected to be applied to debt paydown
- Cash flow framing (analyst Q&A): CFO/CEO endorsed an illustrative estimate of ~similar inflow as last year; another analyst penciled ~$20M annual free cash flow based on (EBITDA $40M–$44M minus $5M–$6M CapEx, ~low cash taxes, interest ~$20M, and working capital source ~$5M–$6M) — Dak agreed broadly; interest expected slightly under $20M
Strategy & Ops
- Manufacturing transfer: transferring production from L.A. to Alabama to maximize production efficiencies
- Business improvement initiative: transformation transitioned from external/previous listing to internal ownership; planned transformation spend reduced from $2M in Q3 2025 vs $8M in Q3 2024 to negligible over coming quarters
- Renaming non-crop business to “Specialty” to better reflect technology/patents; accounting nomenclature expected to update in future financials
- SIOP process improvements: less inventory; inventory replacement cost funneled through P&L after working off old inventory (margin benefit)
- International decisions: Brazil strategic decision to drop lower-margin business to focus on higher margin customers/products
Market Outlook
- Full-year 2025 adjusted EBITDA maintained at $40M–$44M (despite agricultural down cycle/trade uncertainty)
- Full-year 2025 net sales lowered to $520M–$535M (from prior expectations implied in Q&A; management: primarily Mexico, Central America, Australia)
- Gross margin/Q4 dynamic: CEO expects costs savings to “stick” though R&D historically higher in Q4; R&D forecast below last year
- Pipeline growth: ~$100M net sales medium-term; product sales not expected to materially “fruition” until starting in 2028 (2–3 year product development cadence; “not going to be there” in 2026, more into 2027–2029)
Risks & Headwinds
- Tariff/trade uncertainty: trade tensions with China creating a cloud over industry and soybean channel uncertainty; management did not quantify tariffs in the transcript but explicitly discussed tariff impact analysis and mitigation (see below)
- Agricultural weather impacts: drought in key regions of Australia; Central America weather pattern impacts; Mexico not fully destocked
- Potato market weakness: continued weakness impacted soil fumigant sales
- Specialty demand drag from product liability matter: drag in first part of Q3; reimbursement expected but accounting mitigation issue (no indemnification asset recorded yet due to insufficient information)
- Competitive/generic pressure: analyst asked about increased generic pressure; management responded they did not see significantly different impact; cited preparedness for ongoing generic competition
Sentiment: MIXED
Note: This summary was synthesized by AI from the AVD Q3 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.